Madrigal Pharmaceuticals, Inc. MDGL
432.79 USD +33.16 (+8.30%)
At closeNov 9, 2026, 4:00 PM EST
432.79 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
402.00 Day range 438.74
353.54 52-week range 615.00
- YTD
- -25.68%
- 1 year
- -11.54%
News
newsfilecorp.com Kaplan Fox Announces a Securities Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) - Investors Encouraged to Contact the Firm New York, New York--(Newsfile Corp. - November 9, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
businesswire.com MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $MDGL--MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
globenewswire.com MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP RADNOR, Pa., Nov. 07, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the…
prnewswire.com Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP RADNOR, Pa., Nov. 6, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the…
newsfilecorp.com Kaplan Fox & Kilsheimer LLP Encourages Madrigal Pharmaceuticals, Inc. (MDGL) Investors to Contact the Firm Regarding Potential Securities Law Violations New York, New York--(Newsfile Corp. - November 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
benzinga.com Madrigal Pharmaceuticals Announces Data From Its Rezdiffra Trials Demonstrated 55% Participants Achieved Over 25% Improvement In Liver Stiffness, 48% Patients Reports Over 30% Improvement At 12 Months Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced…
globenewswire.com Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra CONSHOHOCKEN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In Q4 Healthcare stocks Alnylam, Madrigal and Corcept appear oversold, with RSI near or below 30, offering potential opportunities for investors.
defenseworld.net Reviewing Madrigal Pharmaceuticals (NASDAQ:MDGL) & OSR (NASDAQ:OSRH) Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) and OSR (NASDAQ: OSRH - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies…
benzinga.com Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $633 Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $612 to $633.
globenewswire.com MADRIGAL PHARMACEUTICALS, INC. INVESTIGATION: MDGL Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).…
benzinga.com Truist Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $743 Truist Securities analyst Srikripa Devarakonda reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $709 to $743.
newsfilecorp.com Kaplan Fox & Kilsheimer LLP Encourages Madrigal Pharmaceuticals, Inc. (MDGL) Investors to Contact the Firm Regarding Potential Securities Law Violations New York, New York--(Newsfile Corp. - November 4, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
seekingalpha.com Madrigal Q3 Earnings: Why I'm Upgrading The Stock Again In 2026, This Time To Buy Madrigal Pharmaceuticals delivered another earnings beat, with Q3 net sales up 50% YoY, and Rezdiffra's blockbuster status confirmed. Despite exceeding expectations, MDGL shares fell ~8%…
seekingalpha.com Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript
benzinga.com Citigroup Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $760 Citigroup analyst Eric Joseph maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $725 to $760.
marketbeat.com What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings Call Madrigal Pharmaceuticals NASDAQ: MDGL reported third-quarter 2026 net sales of $431.3 million for its MASH treatment Rezdiffra, up 50% from the prior-year period, as the company said it continued to…
benzinga.com Madrigal Pharmaceuticals Q3 2026 Earnings Call Transcript Madrigal Pharmaceuticals (NASDAQ:MDGL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
zacks.com Madrigal (MDGL) Q3 Earnings and Revenues Beat Estimates Madrigal (MDGL) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of a loss of $1.09 per share. This compares to a loss of $5.08 per share a year ago.
benzinga.com Madrigal Pharmaceuticals Q3 EPS $1.83 Beats $(0.94) Estimate, Sales $431.268M Beat $404.264M Estimate Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $(0.94) by 294.68 percent. This is a 136.02 percent increase over…
globenewswire.com Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates CONSHOHOCKEN, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic…
benzinga.com Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffra Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the…
benzinga.com Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and announces $704 price target.- benzinga.com Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725 Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and announces Price Target of $725.
benzinga.com This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold Paulson's hedge fund reduced its equity book to $2.58B in Q2, exiting two positions and opening a stake in Alphabet.
benzinga.com This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinions and price targets for these stocks.- benzinga.com Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target Wolfe Research analyst Andy Chen upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Peer Perform to Outperform and announces $605 price target.
benzinga.com Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962 Barclays analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and lowers the price target from $964 to $962.
benzinga.com Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.50) by 20.4 percent. This is a 4.74 percent decrease over losses…- benzinga.com Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587 Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $578 to $587.
benzinga.com 4 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Wells Fargo Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $685 Wells Fargo analyst Sadia Rahman initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $685.
- benzinga.com Madrigal Pharmaceuticals Receives Three Resmetirom Patents From U.S. Patent And Trademark Office New U.S. Rezdiffra patents in F2/F3 to be listed in FDA’s Orange BookU.S. Patent No. 12,667,575, directed to administering a weight-threshold step-down 60mg or 80mg resmetirom dose for patients with…
- benzinga.com B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542 B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral and lowers the price target from $550 to $542.
- benzinga.com Madrigal Pharma Announces New Analyses Of Phase 3 Data And Real-World Evidence Demonstrating Rezdiffra Reduced Markers Of Cardiovascular And Liver-Related Risk In Patients With MASH Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASHRezdiffra improved atherogenic lipid profiles…
- benzinga.com Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $709 Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $640 to $709.
- benzinga.com Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $578 Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target from $587 to $578.
- benzinga.com Evercore ISI Group Maintains Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $649 Evercore ISI Group analyst Liisa Bayko maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and lowers the price target from $652 to $649.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call - benzinga.com HC Wainwright & Co. Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target HC Wainwright & Co. analyst Andrew S. Fein reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and maintains $620 price target.
- benzinga.com Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.25) per share which beat the analyst consensus estimate of $(3.60) by 9.72 percent. This is a 24.52 percent decrease over…
- benzinga.com Arrowhead Announces Exclusive Worldwide License Agreement With Madrigal For ARO-PNPLA3, Clinical Stage RNAi Therapeutic To Reduce Liver Expression Of PNPLA3 As Potential Treatment For Metabolic Dysfunction-Associated Steatohepatitis - Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH- Phase 1 data published in The New England Journal of…
- benzinga.com Madrigal Pharmaceuticals Announces Exclusive Global License Agreement With Arrowhead Pharmaceuticals For ARO-PNPLA3 Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene,…
benzinga.com Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - benzinga.com Earnings Scheduled For February 19, 2026
benzinga.com Earnings Preview For Madrigal Pharmaceuticals 
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session - benzinga.com Madrigal Pharmaceuticals inks an exclusive global license agreement with Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals for six preclinical MASH programs For An Upfront $60M And Milestone Payment Of $4.4B Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an…
- benzinga.com Barclays Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $964 Barclays analyst Eliana Merle initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $964.